Curasight and Curium announce global partnership for uTRACE[®] in prostate cancer
· Curasight to develop its proprietary uTRACE[®] PET imaging technology to obtain regulatory approval in EU and USA, with Curium responsible for manufacturing and commercialization · Curasight eligible for up to USD 70 mn in development and commercial milestones as well as double-digit royalties on sales on eventual commercialization · The agreement supports Curasight’s strategy to leverage partnerships as it progresses its uPAR theranostic solution to diagnose and treat certain types of cancerCopenhagen, Denmark, May 1, 2023 – Curasight A/S (“Curasight” or “the Company” – TICKER: